

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Innovative Vaccine Approaches (EK50)

June 28-30, 2021 • Virtual at your computer

Scientific Organizers: Mariagrazia Pizza, Galit Alter and Gordon Dougan

Sponsored by AstraZeneca, Biologend, Merck & Co., Inc., and Moderna

MONDAY, JUNE 28

Welcoming Remarks and Keynote Address (7am Denver/Mountain Time Start)

- ***Mariagrazia Pizza**, GlaxoSmithKline Vaccines, Italy
- ***Galit Alter**, MIT and Harvard University, USA
- Rino Rappuoli**, GlaxoSmithKline Vaccines, Italy
Vaccines 2030

Shifting the Paradigm in Global Health and AMR (7:40am Denver/Mountain Time Start)

- ***Keith Klugman**, Bill and Melinda Gates Foundation, USA
- ***Galit Alter**, MIT and Harvard University, USA
- Elizabeth Klemm**, Wellcome Trust, UK
The Role of Vaccines in Combatting Antimicrobial Resistance (AMR)
- Gagandeep Kang**, Christian Medical College/Translational Health Science and Technology Institute, India
Oral Vaccine Induced Immunity in Lower Income Settings
- Ankur Mutreja**, University of Cambridge, UK
Challenges in the Field
- Gavin J. Wright**, Wellcome Sanger Institute/University of York, UK
An Invariant Trypanosoma Vivax Vaccine Antigen Induces Protective Immunity

Mariagrazia Pizza, GlaxoSmithKline Vaccines, Italy
GMMA as Antigen and Delivery System

Sowmya Ajay Castro, University of Dundee, UK
Short Talk: Recombinantly Produced Group A Carbohydrate Backbone Embedded Into Outer Membrane Vesicles Functions as Potent and Efficient Vaccine Candidate Targeting Group A Streptococcus

Joseph Paul Hoffmann, Tulane University School of Medicine, USA
Short Talk: Vaccine Driven Lung TRM Cells Provide Immunity Against Klebsiella via Fibroblast IL-17R Signaling

Meet the Editors (12:30pm Denver/Mountain Time Start)

- Alexandra Flemming**, Nature Publishing Group, UK
- Paula Jauregui Onieva**, PLOS, UK
- Ines Pires**, Frontiers In Tropical Diseases, Switzerland
- Gaia Trincucci**, Journal of Experimental Medicine, USA

Poster Session (1:30pm Denver/Mountain Time Start)

TUESDAY, JUNE 29

COVID and Pan COVID Vaccines: Technologies and Criticalities (7am Denver/Mountain Time Start)

- ***Lynda M. Stuart**, Bill & Melinda Gates Foundation, USA
- ***Gordon Dougan**, University of Cambridge, UK
- Galit Alter**, MIT and Harvard University, USA
New Humoral OMIC Tools to Mine for Correlates of Immunity
- Andrea Carfi**, Moderna, USA
mRNA Based Vaccines

Andrew J. Pollard, University of Oxford, UK
Viral Vectors

Florian Krammer, Icahn School of Medicine at Mount Sinai, USA
From Diversity to Protection

Ravi K. Gupta, University of Cambridge, UK
SARS-COV2 Spread and Evolution to Instruct Pan-Vaccine Development Strategies

Caroline E. Wagner, McGill University, Canada
Epidemiological and Evolutionary Considerations of SARS-CoV-2 Vaccine Administration Schemes

Viviane Machado, Inovio Pharmaceuticals Inc., USA
Short Talk: INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants

Kayvon Modjarrad, Walter Reed Army Institute of Research, USA
Short Talk: Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

Pandemic Preparedness: Lessons from COVID (10:25am Denver/Mountain Time Start)

- ***Shabir Madhi**, South African Medical Research Council, South Africa
- ***Christopher L. Karp**, Bill & Melinda Gates Foundation, USA
- Lawrence Corey**, Fred Hutchinson Cancer Research Center, USA
Planning for Correlates for Phase 3 Studies: Lessons from COVID
- Peter Gilbert**, Fred Hutchinson Cancer Research Center, USA
Planning for Correlates for Phase 3 Studies: Lessons from COVID
- Gordon Dougan**, University of Cambridge, UK
Changing Regulatory and Vaccine Landscape in the Face of COVID
- Nicole Lurie**, Coalition for Epidemic Preparedness Innovations - CEPI, USA
Strategies to Manufacturing, Distribution and Roll-out

Career Roundtable (1:30pm Denver/Mountain Time Start)

- Sanjay Ram**, University of Massachusetts, USA
- Amy E. Gilbert**, Adaptive Biotechnologies, USA
- Elizabeth Klemm**, Wellcome Trust, UK

WEDNESDAY, JUNE 30

Immune Correlates: 'In vivo' and 'in vitro' Model Systems (7am Denver/Mountain Time Start)

- ***Gordon Dougan**, University of Cambridge, UK
- ***Mariagrazia Pizza**, GlaxoSmithKline Vaccines, Italy
- Pamela J. Bjorkman**, California Institute of Technology, USA
Towards a Pan-Sarbecovirus Vaccine
- Christopher Chiu**, Imperial College London, UK
SARS-Cov2 Human Challenge
- Elisa Nemes**, University of Cape Town, South Africa
Immune Correlates of Protection from Tuberculosis
- Stephen Gordon**, Liverpool School of Tropical Medicine, UK
Pneumococcal Human Infection Study in Malawi to Understand Vaccine Efficacy
- Andrew Steer**, Murdoch Children's Research Institute, Australia
Human Infection Model of Group A Streptococcus Pharyngitis

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Innovative Vaccine Approaches (EK50)

June 28-30, 2021 • Virtual at your computer

Scientific Organizers: Mariagrazia Pizza, Galit Alter and Gordon Dougan

Sponsored by AstraZeneca, Biologend, Merck & Co., Inc., and Moderna

Thomas Rudel, University of Würzburg, Germany

Innovative 3D Infection Models as Validation Tools for Vaccine Research

Catherine A. Blish, Stanford University School of Medicine, USA

Single Cell Omics from SARS-COV2 Spread and Evolution to Instruct Pan-Vaccine Development Strategies

John Tyler Sandberg, Karolinska Institutet, Sweden

Short Talk: Activation and Kinetics of Circulating Tfh Cells, Specific Plasmablast Response and Development of Neutralizing Antibodies Following Yellow Fever Virus Vaccination

Kiva V. Brennan, Trinity College Dublin, Ireland

Short Talk: Cytosolic dsRNA Improves Neonatal Innate Immune Responses to Adjuvants Currently in Use in Paediatric Vaccines

Closing Remarks (10:50am Denver/Mountain Time Start)

***Gordon Dougan**, University of Cambridge, UK

Networking Lounge (11am Denver/Mountain Time Start)